Capricor Therapeutics Signs Binding Term Sheet With Nippon Shinyaku For Europe Expansion And Commercialization Of Deramiocel In Duchenne Muscular Dystrophy; Capricor to Receive $15M Equity Investment, $20M Upfront Payment Upon Signing Definitive Agreement, Up To $715M In Potential Milestones And Double Digit Percentage Of Product Revenue
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics has signed a binding term sheet with Nippon Shinyaku for the expansion and commercialization of Deramiocel in Europe for Duchenne Muscular Dystrophy. Capricor will receive a $15M equity investment, a $20M upfront payment, up to $715M in potential milestones, and a double-digit percentage of product revenue.
September 17, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics has entered into a significant partnership with Nippon Shinyaku for the commercialization of Deramiocel in Europe, which includes a $15M equity investment, a $20M upfront payment, and potential milestones up to $715M.
The partnership with Nippon Shinyaku is a major development for Capricor, providing immediate financial benefits and long-term revenue potential. The $15M equity investment and $20M upfront payment improve Capricor's financial position, while the potential $715M in milestones and double-digit revenue share offer significant future earnings. This news is likely to positively impact Capricor's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100